UX023: Interim Phase II data

Interim data from the open-label, U.S. Phase II UX023T-CL201 trial showed that 6 of 8 patients with TIO or epidermal nevus syndrome receiving subcutaneous KRN23 every 4 weeks for 48 weeks achieved ser...